Research | No Babies Blister

The Challenge

Why EB Hasn't Been Cured Yet

Most EB research done to date has failed in two critical ways: it only treats the skin surface rather than the whole body, and it produces solutions that are far too expensive for global access.

Surface-Only Treatments

Most approved creams only address visible skin symptoms. But what you see on the skin is also happening inside — the esophagus, airways, and intestines all require treatment.

Unaffordable Solutions

Some experimental therapies cost millions per patient. With 500,000 EB sufferers worldwide — many in developing nations — affordability isn't optional, it's a moral imperative.

Orphan Disease Neglect

Big pharma avoids orphan diseases. Government research funding is insufficient. Independent research organizations like ours are the only path forward.

Our Approach

What Sets Our Fast Cure Plan Apart

Our team brings unmatched expertise: FDA navigation, genetic skin therapy patents, and a commitment to affordable solutions that reach every child on earth.

Gene Therapy

We replace mutated skin gene proteins with healthy gene proteins to stop blistering and skin cancer at the molecular level. Healthy genes produce healthy skin proteins that keep skin from blistering off.

ProgressPhase II — 65%

Systemic Full-Body Treatment

Unlike topical creams, our approach targets EB systemically — treating the entire body from the inside out, including internal organs and the digestive tract where EB also causes damage.

ProgressPhase I — 45%

Natural Molecular Therapy

We research affordable natural compounds that reduce inflammation, control itching, and accelerate skin healing — making treatment accessible globally regardless of economic constraints.

ProgressPhase II — 72%

The Team

Our World-Class Medical Team

Our researchers combine cutting-edge science with real-world FDA experience to ensure our cure reaches patients as quickly and affordably as possible.

Johns Hopkins Physicians

Dr. Aaron Tabor, MD and colleagues with elite clinical training in genetic and skin diseases.

Genetic Therapy Experts

Researchers holding patents in genetic skin therapy and pioneering gene editing methodologies.

FDA Pathway Navigators

In-depth experience navigating FDA approval pathways to ensure treatments reach market efficiently.

Global Partners

Collaborative network of researchers, hospitals, and scientific institutions across multiple countries.

Timeline

Research Milestones

Our research progresses deliberately and methodically — every phase brings us closer to the day no child has to suffer from EB.

Current Funding Status

Annual Research Budget$2.4M needed

68% funded through donor contributions

Fund Our Research

2019 — Completed

Fast Cure Plan Conceived

Dr. Tabor assembles the medical team and outlines the multimodal approach combining gene therapy, systemic treatment, and natural molecular research.

2020 — Completed

Preclinical Research Initiated

Laboratory research begins on the gene therapy model. Natural ingredient molecular studies commence. First promising biomarkers identified.

2021-2022 — Completed

Phase I Clinical Trials

Phase I safety trials for gene therapy initiated. Preliminary results show the approach is safe and demonstrates measurable improvement in skin protein production.

2023-2025 — In Progress

Phase II Efficacy Studies

Phase II trials expanding. Gene therapy showing 65% progress. Natural molecular therapy at 72% with promising reduction in inflammation markers. Systemic approach in Phase I at 45%.

2026-2027 — Planned

FDA Fast-Track Application

Leveraging our team's FDA expertise to pursue accelerated review pathways for the most promising treatment. Goal: first approved affordable EB systemic therapy.

2028+ — Goal

Affordable Cure — Global Access

Full-body systemic cure available globally at an affordable price. No child left without access to treatment regardless of their country or family's financial situation.

Our Fast Cure Plan